论文部分内容阅读
目的探究门冬胰岛素(诺和锐)联合重组甘精胰岛素对2型糖尿病患者的治疗效果,为联合疗法的应用提供可靠的依据。方法 48例2型糖尿病患者作为研究对象,按照随机分配的原则将其分为实验组及对照组,各24例。实验组接受诺和锐联合重组甘精胰岛素治疗,对照组仅接受诺和锐治疗。观察比较两组患者的治疗效果。结果经过治疗,实验组血糖达标时间为(2.8±0.3)d,低血糖发生率为4.2%;对照组血糖达标时间为(3.2±0.5)d,低血糖发生率为33.3%;实验组血糖达标时间短于对照组、低血糖发生率低于对照组,差异均具有统计学意义(P<0.05)。两组空腹血糖、用药2 h后血糖水平比较差异均无统计学意义(P>0.05)。结论采用联合疗法(诺和锐联合重组甘精胰岛素)治疗2型糖尿病的效果较常规疗法(单用诺和锐)好,值得推广。
Objective To investigate the therapeutic effect of aspart insulin (Novo-Rui) combined with recombinant insulin glargine on patients with type 2 diabetes mellitus, and to provide a reliable basis for the combination therapy. Methods Forty-eight patients with type 2 diabetes mellitus were divided into experimental group and control group according to the principle of random assignment. The experimental group received Novo and Rui combined recombinant insulin glargine, the control group received only Nuo Rui treatment. Observed and compared the treatment effect of two groups of patients. Results After the treatment, the time of reaching the target blood glucose in the experimental group was (2.8 ± 0.3) d and the incidence of hypoglycemia was 4.2%. The control group had a blood glucose level of (3.2 ± 0.5) d and the incidence of hypoglycemia was 33.3% The time was shorter than the control group, the incidence of hypoglycemia was lower than that of the control group, the differences were statistically significant (P <0.05). There was no significant difference in fasting blood glucose between the two groups after 2 h of medication (P> 0.05). Conclusions Combination therapy (Novartis combined with recombinant insulin glargine) is more effective than conventional therapy (Novolin alone) in the treatment of type 2 diabetes and is worth promoting.